Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov enrollment closed early-phase tilt small index

Renal Transplant Recipient: early-phase trial registry

A small indexed set (2 trials) with no open enrollment listed right now.

Corpus placement: #7,188 of 28,707 conditions by registered trial count.

2 US clinical trials · none currently recruiting · #7,188 of 28,707 conditions by registered trial count

Renal Transplant Recipient: 2 US clinical trials tracked, none currently recruiting.

Renal Transplant Recipient is the subject of 2 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is National Institute of Allergy and Infectious Diseases (NIAID), running 1 of these trials.

Enrollment posture brief

Registry condition renal-transplant-recipient

OPEN 0 | RECR 0% | LATE 0 | EARLY 2 | RANK #7188 | SPON 1

Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Renal Transplant Recipie (th…0%
Open-enrollment share among volume-matched conditions near Renal Transplant Recipient

Renal Transplant Recipient has no open enrollment in this registry pull (2 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Renal Transplant Recipient on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Renal Transplant Recipient is recruiting below its size-band peers.

    0 of 2 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 11Phase 21

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 1

Named interventions

Most-linked intervention names on Renal Transplant Recipient records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

belatacept Drug
1 trials
alemtuzumab Drug
1 trials
Donor-derived Mesenchymal Stromal Cells Biological
1 trials
mycophenolate mofetil Drug
1 trials
sirolimus Drug
1 trials
Belatacept Drug
1 trials
Abatacept Drug
1 trials

US sites by state

Facility locations filed on Renal Transplant Recipient trials. A trial with sites in several states counts in each.

North Carolina 1 trials
Georgia 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Renal Transplant Recipient page

2 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Renal Transplant Recipient condition card totals 2 registered trials; most-linked intervention belatacept; top US site state North Carolina. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.